Advertisement

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Apr
09
Today In Oncology
Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis
Long-Term Outcomes With Pralsetinib in RET Fusion–Positive NSCLC
IMPT vs IMRT in Oropharyngeal Cancer
Metastatic Papillary Renal Cancer Final Results With Savolitinib and Durvalumab
Damaging Missense Variants in Innate Immunity Genes Linked to Earlier Breast Cancer Onset in BRCA1 Carriers
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo